INVENTISBIO CO., LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.01 CNY | +1.01% |
|
+2.56% | -33.88% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 129M 17.88M | Sales 2025 * | 320M 44.29M | Capitalization | 5.77B 799M |
|---|---|---|---|---|---|
| Net income 2024 * | -288M -39.86M | Net income 2025 * | -255M -35.29M | EV / Sales 2024 * | 44.7 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 18 x |
| P/E ratio 2024 * |
-20
x | P/E ratio 2025 * |
-19
x | Employees | 222 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 44.6% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.01% | ||
| 1 week | +2.56% | ||
| Current month | +2.56% | ||
| 1 month | -5.03% | ||
| 3 months | +10.85% | ||
| 6 months | -43.16% | ||
| Current year | -33.88% |
1 week
9.76
10.13
1 month
7.9110.57
Current year
7.4015.30
1 year
7.4021.57
3 years
7.4023.80
5 years
7.4023.80
10 years
7.4023.80
| Managers | Title | Age | Since |
|---|---|---|---|
Yao Lin Wang
CEO | Chief Executive Officer | 61 | 13-01-10 |
Lu Wei Shi
DFI | Director of Finance/CFO | 39 | 14-12-31 |
Ling Zhang
CTO | Chief Tech/Sci/R&D Officer | 60 | 17-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yao Lin Wang
CEO | Chief Executive Officer | 61 | 13-01-10 |
Xin Miao Dai
BRD | Director/Board Member | 61 | 20-12-08 |
Yue Heng Jiang
BRD | Director/Board Member | 53 | 17-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 10.01 | +1.01% | 4,924,945 |
| 24-05-06 | 9.91 | +1.54% | 7,365,244 |
| 24-04-30 | 9.76 | -2.11% | 11,219,980 |
End-of-day quote Shanghai S.E., May 06, 2024
More quotes
InventisBio Co Ltd is a China-based company mainly engaged in the research and development of innovative drugs. The Company's main product is still in clinical development. The Company's core products mainly focus on major disease areas such as oncology and metabolic diseases. The Company's products include D-0120, D-0502, D-1553, BPI-D0316 and others.
Calendar
2024-08-19
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
10.01
CNY
Average target price
18.5
CNY
Spread / Average Target
+84.82%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.88% | 800M | |
| +10.44% | 107B | |
| +0.82% | 106B | |
| +8.09% | 23.47B | |
| -13.89% | 21.9B | |
| -5.94% | 18.77B | |
| -37.26% | 17.85B | |
| -10.98% | 16.78B | |
| +8.67% | 14.41B | |
| +41.08% | 12.86B |
- Stock Market
- Equities
- 688382 Stock